Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015 (2015), Article ID 307453, 15 pages
http://dx.doi.org/10.1155/2015/307453
Research Article

The Clinical Relevance of IL-17-Producing CD4+CD161+ Cell and Its Subpopulations in Primary Sjögren’s Syndrome

Department of Rheumatology & Immunology, Clinical Immunology Center, Peking University People’s Hospital, 11 Xizhimen South Street, Beijing 100044, China

Received 15 April 2015; Revised 12 August 2015; Accepted 12 August 2015

Academic Editor: Ethan M. Shevach

Copyright © 2015 Linbo Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

We compared Hb levels in pSS patients with elevated or normal percentages of CD4+CD161+ T cell subsets. There was no difference in Hb levels between patients with elevated and normal CD4+CD25+CD161+ T cell subset or the overall CD4+CD161+ T cell subset. The Hb level in patients with elevated CD4+CD25-CD161+ subset was significantly higher than that in patients with normal CD4+CD25-CD161+ subset (Table S1). To evaluate the potential function of CD4+CD25+CD161+ T cell subset, we compared the expression of Foxp3 and Helios of CD4+CD25+CD161+ and CD4+CD25+CD161- T cell subsets. It was very obvious that the CD4+CD25+CD161+ T cells expressed significantly decreased levels of Foxp3 or Helios than the CD4+CD25+CD161- T cell subset (Supplementary Fig.1). We further evaluated the expression levels of these two transcription factor of CD4+CD25+CD161+ and CD4+CD25+CD161- T cell subsets in both pSS patients and healthy controls (Supplementary Fig.2). In healthy subjects, the CD4+CD25+CD161+ T cells expressed significantly decreased levels of Foxp3 or Helios than the CD4+CD25+CD161- T cell subset. However, both CD4+CD25+CD161+ and CD4+CD25+CD161- T cell subsets in healthy people expressed less Foxp3 and Helios than their counterparts in pSS patents.

  1. Supplementary Material